Regulation of gene expression at the level of transcriptional elongation has been shown to be important in stem cells and tumour cells, but its role in the whole animal is only now being fully explored. Neural crest cells (NCCs) are a multipotent population of cells that migrate during early development from the dorsal neural tube throughout the embryo where they differentiate into a variety of cell types including pigment cells, cranio-facial skeleton and sensory neurons.
Introduction
RNA polymerase pausing and transcriptional elongation is important in the specification of many types of cells including embryonic stem (ES) cells. In order for genes to undergo transcription, RNA polymerase II (Pol II) must be recruited to the promoter region (Hochheimer and Tjian, 2003) . Subsequent to this, RNA Pol II may undergo regulation to temporally control the expression of genes in specific cell types. Such regulation includes the promoter proximal pausing of Pol II, the process by which Pol II undergoes stalling or poising at the 5' end of a gene just downstream of the transcription start site (Core and Lis, 2008) . This occurs due to binding of pause factors, DRB-sensitivity inducing factor (DSIF), negative elongation factor (NELF) and Gdown1 (Cheng et al., 2012; Wada et al., 1998; Yamaguchi et al., 1999) . In order for transcriptional elongation to commence the positive transcription elongation factor (P-TEFb) must be recruited to the transcription elongation complex. PTEFb is known to be a complex composed of cyclin dependent kinase 9 (CDK9) and cyclin T1 (Bres et al., 2008; Fujita et al., 2009; Jonkers and Lis, 2015; Kohoutek, 2009) . To initiate transcriptional elongation, P-TEFb phosphorylates serine2 of the c-terminal domain (CTD) of Pol II and the SPT5 subunit of DSIF.
After this phosphorylation, NELF dissociates from the complex and transcriptional elongation begins (Fujita et al., 2009) . This process occurs when P-TEFb is in its active form and part of a collective of several proteins, termed the super elongation complex (SEC), which is known to regulate transcriptional elongation (Luo et al., 2012a; Zhou et al., 2012) .
The SEC is recruited to the promoter region of genes when rapid transcription is required in response to specific developmental signals, changes to available nutrition or even acute temperature change. It is because of this that the genes primarily regulated by RNA polymerase pausing are master regulator genes and/or rapid response genes such as heat shock and serum inducible genes (Fuda et al., 2009; Luo et al., 2012b) . It has also been suggested that the main function of SEC recruitment to paused genes is not necessarily to allow rapid induction but also to synchronise genes in development (Boettiger and Levine, 2009) . Work in Drosophila and ES cells has shown that transcription elongation is not important globally within the genome but is found to regulate 10-40% of genes. Some of these genes have been identified as crucial developmental control genes (Gaertner and Zeitlinger, 2014; Zeitlinger et al., 2007) .
The neural crest is a transient embryonic cell population found exclusively in vertebrates. Neural crest cells (NCCs) migrate from the dorsal neural tube to various parts of the embryo where they differentiate to give rise to a diverse set of cell types (Milet and Monsoro-Burq, 2012; Pegoraro and Monsoro-Burq, 2013; Sauka-Spengler and Bronner-Fraser, 2008) . These include enteric ganglia, neuroendocrine cells, melanophores, and craniofacial skeletal and connective tissue, thus NCCs are multi-potent progenitors. Their induction and specification begins during the early gastrula stage of development and continues throughout organogenesis. This process depends on multi-module gene regulatory networks acting between the neural plate, non-neural ectoderm and paraxial mesoderm (Buitrago-Delgado et al., 2015; Hoppler and Wheeler, 2015; Huang and Saint-Jeannet, 2004; Sauka-Spengler and Bronner-Fraser, 2008) . Multiple signals and transcription factors are responsible for neural crest (NC) properties such as multipotency, induction, specification, migration and differentiation (Sauka-Spengler and BronnerFraser, 2008) .
Once the neural plate border is fully specified and NCCs have been induced, neural crest specifiers begin to act (Milet and Monsoro-Burq, 2012 ).
These include the transcription factors Snail1, Snail2 (Slug), Sox8, Sox9, Sox10, FoxD3, and c-Myc. After specification morphological changes in the neural crest cells including changes to shape, adhesion and cell motility enable the cells to migrate from the dorsal neural tube (Sauka-Spengler and BronnerFraser, 2008) . Neural crest specifiers can be separated into two groups; early and late NC specifiers. Expression of early neural crest specifiers, including cMyc, and Snail1, is first identified at the neural plate border, whilst expression of slightly later neural crest specifiers such as Snail2 and FoxD3 is seen in premigrating neural crest and can continue throughout migration. Only after these have all started to be expressed does expression of members of the SoxE family such as Sox10 start (Sauka-Spengler et al., 2007) . It has been suggested that the early neural crest specifier c-Myc may have a role in maintaining neural crest cell multipotency and proliferation by maintaining a balance between cell death and proliferation following NC specification (Bellmeyer et al., 2003; Kee and Bronner-Fraser, 2005; Light et al., 2005) .
Using chemical genetic screens we have previously identified small molecules that affect pigment cell development (Tomlinson et al., 2005; Tomlinson et al., 2009a; Tomlinson et al., 2009b) . One of these, the small molecule leflunomide, inhibits pigment cell development in Xenopus and Zebrafish (Elworthy et al., 2003; Tomlinson et al., 2009b; White et al., 2011) . In addition, leflunomide inhibits melanoma tumour growth in tissue culture and in mouse xenografts. Leflunomide inhibits the enzyme dihydro-orotate dehydrogenase, a rate limiting enzyme in the pyrimidine biosynthesis pathway.
It acts to inhibit transcriptional elongation of genes required for neural crest development and melanoma growth by limiting the pool of pyrimidines in the cell (White et al., 2011 ).
Here we further investigate leflunomide's ability to inhibit transcriptional elongation during neural crest development and show that it prevents expression of both, early and late neural crest specifiers such as Snail2, Sox10
and FoxD3 and c-Myc. As leflunomide acts through inhibiting transcriptional elongation we speculated that regulation of transcriptional elongation could be crucial for neural crest development. We therefore characterised the temporal and spatial expression of components of the Positive Transcription Elongation Factor B (P-TEFb) complex, Cdk9 and CyclinT1, during neural crest development in X. laevis. CDK9 and CYCLINT1 loss-of-function analyses by morpholino knockdown closely mimic the phenotypes induced by leflunomide treatment. Interestingly, we identify c-Myc as a gene susceptible to regulation of transcriptional elongation in the early NC and show that it is able to rescue CDK9 and CYCLINT1 morphant phenotypes. This is backed up by ChIP sequencing data of Xenopus embryos which shows the c-Myc gene to be one of the most 'paused' genes in the genome. We thus propose regulation at the level of transcriptional elongation to be important in NC development through the driving of c-Myc expression.
Results

The expression of the P-TEFb complex components during Xenopus laevis development
We have previously shown that inhibition of transcriptional elongation leads to defects in neural crest development (White et al. 2011 ). An important regulator of transcriptional elongation is the P-TEFb complex. We therefore decided to investigate the role of the components of the P-TEFb complex during Xenopus development. The P-TEFb complex is comprised of CDK9 and CYCLINT1. Expression analysis showed Cdk9.S, Cdk9.L and CyclinT1 to be expressed in the neural plate and neural plate border of neurula stage embryos (Fig. 1) . In tailbud stage embryos at stages 26 and 32 expression was seen in the NC derived branchial arches. To determine if their expression overlapped with the NC, we carried out double in situ hybridisations at st16 for all three PTEFb components with the neural crest marker Sox10. Expression of the Cdk9.S, Cdk9.L and CyclinT1 overlapped with expression of Sox10, indicating that the P-TEFb complex is expressed in neural crest cells (Fig. 1) .
Leflunomide treatment affects the development of neural crest derivatives
Leflunomide was identified as an inhibitor of NC as a result of chemical screens carried out with the aim to look for small molecules that affect pigment cell development. Our previous results concentrated on the effects of leflunomide on zebrafish neural crest (White et al., 2011) . Here we look at the effects of leflunomide in more detail on Xenopus neural crest. Leflunomide inhibits the formation of Xenopus laevis melanophores in a dose dependent manner and causes a loss of melanophores when added to the embryo after gastrulation ( Fig. 2A and B) . Initially, a leflunomide dose response was used to establish the general phenotype induced by the compound. DMSO treated embryos served as a control. Embryos were treated at a range of concentrations from stage 15 and analysed at stage 38 (Fig. 2Ai) . Leflunomide treatment led to a loss of melanocytes in the underside of the tail, head and lateral stripe of the embryo (Fig. 2Ai black arrow heads) . This phenotype was dose dependant, with 60 μM leflunomide demonstrating the most severe phenotypes occurring in a significant number of embryos (Fig. 2Bi) . Treating Xenopus embryos at earlier stages showed a stronger effect on pigment cell development along with a shortened axis ( Fig. 2Aii and Bii).
Leflunomide inhibits transcription of neural crest specifier genes.
Next, we looked at how leflunomide treatment affects the expression of genes known to play a role at different stages of neural crest development.
Embryos were treated with 60 μM leflunomide or DMSO from fertilisation and examined by in situ hybridisation for different markers of neural crest development ( Fig. 2C and D) . The expression of the neural plate border markers Zic1, Zic3 and Pax3 did not change after leflunomide treatment when compared to the DMSO control (Fig. 2C) . This suggests that leflunomide does not interfere with these early stages of neural crest development. There was also no significant change seen in Sox2 expression throughout the neural plate (Fig. 2C) suggesting that neural development is largely unaffected by leflunomide treatment. We next tested genes known to play a role in neural crest specification. The earliest neural crest specifier gene, which showed a loss in expression was c-Myc. This gene gave an interesting expression pattern as it appeared that leflunomide-mediated inhibition of c-Myc expression was restricted to the areas fated to become neural crest ( Fig. 2D black arrows) .
Loss of c-Myc expression was not observed in more posterior neural domains.
Later neural crest specifiers, such as Sox10, were also significantly reduced after leflunomide treatment (Fig. 2D black arrows) and also shown to be only affected in the NC as expression in the otic vesicle (ear) was not affected (Fig.   S8 ). In addition we examined the neural crest specifiers Slug/Snail2 and FoxD3 (Fig. 2D) . Many embryos showed a partial loss or an alteration in the expression of these genes. Quantification of these results (Fig. S1 A) showed that c-Myc and Sox10 show the strongest loss of expression. These results were confirmed by qRT-PCR on whole embryos (Fig. S1 B) . Using this technique we found that neural plate border markers Zic1, Zic3, Pax3 and the neural plate marker Sox2 displayed no significant change in expression level (Fig. S1 B) . Similarly to the in situ hybridisation data we saw a significant decrease in expression of neural crest specifying genes c-Myc, Sox10, Slug/Snail2, and Sox9 (Fig. S1 B) .
RNA sequencing carried out on animal caps treated with leflunomide
To characterise the tissue specific effects of leflunomide treatment we carried out RNA sequencing on animal cap explants induced to become neural crest, neuroectoderm or ectoderm. Animal caps were cut at stage 9 and immediately immersed into either 60 μM leflunomide or DMSO and allowed to develop until stage 15. The genes predominantly down-regulated in the neural crest animal cap sample were genes involved in neural crest specification and general development (Fig. 2E and Fig. S1 C) . Most of these genes, were previously identified to be affected by in situ hybridisation such as c-Myc, Sox10, FoxD3, Slug/Snail2 and Sox9. Interestingly Snail1 expression was not affected by leflunomide. In agreement with our in situ data, we saw no change in neural plate markers, such as Sox1 and Sox2, or neural plate border markers, such as Zic1, Zic3 and Pax3. Other categories of down regulated genes included genes involved in eye development and metabolism, both of which are closely associated with neural crest development. Interestingly we saw downregulation of heat shock genes (Hsp90aa1.1, Hsp105 and Hsp110), which were some of the first genes suggested to be controlled by RNA polymerase pausing and transcriptional elongation (Andrulis et al., 2000; Keegan et al., 2002; . The neuroectoderm sample showed a decrease in the expression of genes, which restrict neuroectoderm fate e.g. Grainyhead-like 3, suggesting an increase in neuroectoderm cell fate. The ectoderm sample showed no significant increase or decrease in any other genes suggesting that regulation of transcriptional elongation is not important for ectoderm development. These results indicate that interference with transcriptional elongation in this system mostly affects neural crest development. We found expression of c-Myc to be slightly downregulated in the neural crest sample with no change seen in the neuroectodem sample and it only shows low expression in the ectoderm. This result agrees with the in situ hybridisation results obtained (Fig. 2D) . The small decrease in the NC sample is likely due to a masking of any decrease by contaminating neural tissue, which is always found in the NC animal caps. A full list of all genes affected in all three sample types can be found in Supplementary data 1. Overall, this data confirmed our findings that leflunomide acts to inhibit NC development and that this could be due to inhibition of transcriptional elongation.
Knockdown of the P-TEFb components leads to defects in neural crest development
To determine the requirement of the P-TEFb complex and subsequent transcriptional elongation for NCC development, we carried out knockdown studies of the individual components. We obtained morpholinos ( We next carried out in situ hybridisation using neural plate border genes, neural crest specifier genes and a neural plate marker. Embryos were injected with a standard control Morpholino, CDK9.S morpholino or the CYCLINT1 morpholino along with 300 pg of LacZ cRNA into one cell of a two-cell stage, with the non-injected half serving as control (Fig. 3B Fig. S3D and Fig. S7 ).
The expression of neural plate border markers Zic1, Zic3 and Pax3 were not affected (Fig. 3B) . The Neural plate marker Sox2 and other neural genes were not affected (Fig 3B and S5) . c-Myc and Sox10 however, showed a striking knockdown after CDK9.S-MO or CYCLINT1-MO (Fig. 3B) . Loss of c-Myc was seen specifically in the anterior patches, which give rise to NC (black arrows Fig. 3B ). Complete loss of Sox10 expression was seen in the NC (black arrows Fig. 3B ). These results were confirmed using qRT-PCR (Fig. S4C) . The same experiment was carried out after injection of the CDK9.L MO, or a combination of the CDK9.S and CDK9.L MOs and this data is shown in Fig. S4A and B.
When embryos were allowed to progress to stage 26 an effect on Sox10 expression in the cranial NC can be seen but no change in expression of Sox10 is seen in the otic vesicle (Fig. S8) . In Leflunomide treated embryos Sox10 expression in the otic vesicle is also not affected while there is a loss of expression in the cranial NC and pigment cells (Fig. S8) . Other neural crest markers Slug/Snail2, FoxD3 and Sox9 show some alteration and partial loss of expression, but very little complete loss of expression ( Fig. 3B and Fig. S4 ). In support of the RNA-Seq data expression of Snail1, which is also an early specifier of NC, was not affected by knockdown of P-TEFb components (Fig.   S7 ). The phenotypes after P-TEFb knock-down were strikingly similar to those obtained after leflunomide treatment (Figs. 2C and D) . c-Myc is also known to regulate the development of trigeminal placodes in the anterior region of the embryo. We therefore looked at the expression of placodal markers by WISH. The placode markers we used include Tbx2, NeuroD and ElrD, which are expressed in the trigeminal placodes and the neural tube (Green and Vetter, 2011; Schlosser and Ahrens, 2004; Showell et al., 2006) . We were able to detect a loss of expression of all three markers, specifically in the trigeminal placode region, but not in any of the other tissues in which they are expressed ( Fig. 3C and Fig. S4D ).
c-Myc is a paused gene during development
As c-Myc is the earliest gene to be affected by Leflunomide and the knockdown of the P-TEFb components, we looked at the RNA pol II occupancy profile of c-Myc and compared it to the promoter histone modification H3K4me3 and the processive elongation mark H3K36me3. These data suggest that cMyc is in a paused or poised state during mid to late gastrula just before the NC are specified (Fig. 4A) . We next carried out RNA Pol II ChIP-seq on embryos injected with CDK9.S morpholino compared to embryos injected with control morpholino. Knockdown of Cdk9 causes an increase in RNA Pol II occupance, the effect of which is the stongest on the promoter, suggesting that there is an increase in pausing of c-Myc (Fig 4A, blue tracks) . We determined shown by the blue spot. While the RPKM on its gene body is increased from 5 to 10, the RPKM on its TSS goes from 11 to 50. This suggests that c-Myc is particularly sensitive to control of expression at the level of transcriptional elongation and is therefore in a more 'paused' state.
c-Myc is regulated by transcriptional elongation in neural crest cells
We postulated that c-Myc could be the primary gene regulated by transcriptional elongation in neural crest cells. We therefore examined if loss of Sox10 expression after P-TEFb morpholino injection could be rescued by co-injecting c-Myc RNA. For this experiment CDK9.S morpholino and CYCLINT1 morpholinos were injected alone or with 100 pg of c-Myc and 500pg of c-Myc RNA. As before, knockdown of CDK9.S and CYCLINT1 led to a high number of embryos displaying loss of Sox10 expression (Fig. 5A and B) . Co-injection of these morpholinos with 100 pg of c-Myc resulted in a reduction of the number of embryos displaying a loss of expression phenotype. The majority of embryos displayed a partial loss phenotype or wild type phenotype. After injection of 500 pg of c-Myc RNA a greater number of embryos displayed a wild type phenotype ( Fig. 5A and B) . Injection of 500 pg of c-Myc alone had very little effect on Sox10 expression and injection of the standard control MO did not affect Sox10 expression (Fig. 5B) . Injection of c-Myc RNA into one blastomere was also shown to rescue leflunomide treated embryos on the injected side (Fig S6) .
Discussion
The molecular mechanisms controlling NCC specification and differentiation are complex and consist of many layers of regulation to ensure the cells decide upon the correct lineage and form the correct cell types. Other multipotent cell types such as embryonic stem cells and haematopoietic stem cells are thought to undergo regulation at the level of transcriptional elongation (Bai et al., 2010; Lin et al., 2011) . It has previously been shown that Foggy mutant Zebrafish, which are deficient in the SPT5 subunit of DSIF, display pigmentation and cardiac defects suggesting a disruption in neural crest development (Keegan et al., 2002) . In addition the Xenopus tropicalis mutant cyd vicious, which displays pigmentation defects, is also mutated in the Spt5 (Fig. 5) .
To investigate whether c-Myc expression was directly regulated by the P-TEFb complex and transcriptional elongation, we looked at cell types other than neural crest cells, which are known to have c-Myc within their gene regulatory network. We reasoned that if c-Myc is a direct target a loss in expression of markers for these other cell types should be observed. Our in situ hybridisation data suggested that c-Myc expression in the placodal regions is lost after knockdown of P-TEFb components (Fig. 3B) , as opposed to more posterior neural expression, which was not affected. We therefore looked at the trigeminal placodes, which are similar to NC and which express c-Myc in the early stages of their gene regulatory network (Bellmeyer et al., 2003; Grocott et al., 2012) . We were able to detect a loss of expression of three markers, specifically in the trigeminal placode region, but not in any of the other tissues in which they are expressed ( Fig. 3C and Fig. S4D ). This provides further evidence for c-Myc itself being directly regulated by transcriptional elongation in specific tissues. Interestingly we also see a loss of Rohon-Beard cell markers (Runx1, Islet1 and Ngnr1) upon knockdown of the P-TEFb complex (Fig S4E) . It is currently not known whether c-Myc signalling is required for the development of these cells. The combination of the loss of neural crest cells, trigeminal placodes and Rohon-Beard cells causes embryos treated with leflunomide or CDK9 morpholino to become insensitive to touch response assays as shown in (Fig S3C and Supp movies 1-3) .
Our ChIP-Seq analysis (Fig 4) shows c-Myc to be a paused gene during early development and that the inhibition of transcriptional elongation by Cdk9 morpholino causes c-Myc to become even more paused compared to the rest of the genome. This is consistent with studies using human 293T embryonic kidney cell lines, which have also shown c-Myc to be a paused gene (Takahashi et al., 2011) . Rahl and colleagues (Rahl et al., 2010) Fig. 6 bottom route) . Recently it has been shown that regulation of transcriptional elongation to be important for genes regulating cell cycle and signal transduction (Williams et al., 2015) . c-Myc is an important regulator for such processes and as we show here it is clearly important in the regulation of the neural crest.
To conclude, we provide evidence that the P-TEFb activation of transcriptional elongation is an important step regulating the correct expression of neural crest genes and that this is mediated through the action of c-Myc. It is possible that a polymerase pausing step is acting to prime c-Myc for transcription to ensure the correct temporal expression of NC genes and therefore a synchronous development of this cell type into its derivatives.
Polymerase pausing has previously been shown to be important in cells, which undergo synchronous gene expression and development. Compared to stochastic uncoordinated gene expression in the whole embryo, the development of the NC requires such synchronous gene expression (Boettiger and Levine, 2009 ). c-Myc has been shown here to be particularly sensitive to inhibition of transcriptional elongation and so it is possible that c-Myc is a paused gene in prospective NC cells (Bai et al., 2010) . There has been much debate in recent literature as to whether this phenomenon of RNA polymerase pausing and regulation of transcriptional elongation is (1) common to all genes and (2) whether it might be specific to certain cell types (Luo et al., 2012b) . Our data contributes to this debate by providing evidence that regulation of transcriptional elongation is focussed on c-Myc and is particularly important in developing neural crest.
Materials and Methods
Embryos, capped RNA synthesis, morpholinos, microinjection and animal capping
All experiments were performed in compliance with the relevant laws and institutional guidelines at the University of East Anglia. The research has been approved by the local ethical review committee according to UK Home Office regulations. Xenopus laevis embryos were obtained as previously described (Harrison et al., 2004) . Embryos were staged using the Nieuwkoop and Faber normal table of Xenopus development (Nieuwkoop, 1994 (Sigma). Embryos were injected at the 2 cell stage in either 1 or both cells. β-Galactosidase activity was detected by colorimetric reaction using Red-Gal (Sigma). Embryos were staged and fixed for 2 hours at room temperature in MEMFA. Animal capping was carried out as previously described (Garcia-
Morales et al., 2009).
Wholemount in situ hybridisation
Single and double in situ hybridisation was carried out as previously described (Harrison et al., 2004) . Probes were synthesised for c-Myc
CDK9.S, CDK9.L and CyclinT1.
Cryosectioning Embryos were fixed in MEMFA for 1 hour, washed twice for 5 minutes in PBST and then put in 30% sucrose for 4 hours at room temperature. Embryos were then transferred to cryomoulds filled with optimal cutting temperature (OCT) compound and left at 4 o C overnight. Embryos were then positioned appropriately for sectioning and left at -20 o C overnight. Embryos were sectioned using the LEICA CM 1950 Cryostat and sections were placed on 5% TESPA slides. Slides were then washed for 5 minutes in PBST and covered with a coverslip using hydromount. Images were taken using a Zeiss CCD upright microscope with colour camera.
Alcian blue staining
Embryos were fixed for 1 hour at room temperature, dehydrated with 5 washes of 100% ethanol (EtoH) for 5 minutes each at RT and then left in Alcian blue staining solution for 3 nights. After this they were washed 3 times for 15 minutes in 95% ethanol at RT then rehydrated in 2% KOH. This was done gradually using 10 minute washes of 75% EtoH in 2% KOH, 50% EtoH in 2%
KOH, 25% EtoH in 2% KOH then 3 2% KOH washes. Embryos were then stored in glycerol to make embryos more transparent. Facial cartilage was then dissected out before imaging. and custom designed by PrimerDesign Ltd, UK where indicated (Rozen and Skaletsky, 2000) . Their oligonucleotide sequences are provided in supplementary table 1. In-house designed primers were synthesized by eurofins (Norwich, UK) and custom primers were designed by and purchased from PrimerDesign Ltd (PrimerDesign Ltd, Southampton, UK).
RNA extraction, PCR, Q-PCR and RNA sequencing
For the RNA seq experiments to determine whether we get a similar loss of neural crest specifying genes compared to the whole embryo data, the animal cap samples were initially tested by in situ hybridisation and RT-PCR.
RNA sequencing was carried out to investigate which genes were affected by leflunomide across the whole genome in the three sample types.
For RNA sequencing total RNA was fragmented before undergoing cDNA library preparation. cDNA was end-repaired, A-tailed and adapter-ligated before amplification and size selection. The prepared libraries undergo quality control by running on a gel and using a bioanalyser to check library fragment size distribution before 100bp paired end sequencing over one lane of a flow cell. Samples were multiplexed 2 x 3 and ran on one lane each to yield approximately 25 million paired reads per sample. Reads were aligned to the Xenopus laevis transcriptome (xlaevisMRNA.fasta) downloaded from Xenbase (release 28/09/12) (Bowes et al., 2008; Langmead and Salzberg, 2012) .
Mapping was carried out with bowtie2 on paired-end samples using default parameters. A custom Perl script was used to parse the bowtie results and count the number of sequences in each sample mapping to every mRNA sequence in the transcriptome file. The table of raw abundances for each mRNA was then read into R and differential expression between untreated and leflunomide treated samples was calculated using the DEseq package (Anders and Huber, 2010) . Any transcript with a p-value of <= 0.05 was classed as being differentially expressed between untreated and leflunomide treated samples.
The data for quantitative RT-PCR experiments were analysed using the 7500FAST software. Measured Ct values for quantitative RT-PCR technical and biological replicates for each gene of interest were analysed using the NORMA-gene algorithm (Heckmann et al., 2011) . NORMA-gene reduces systematic and artificial between-replicate bias utilising the entire data-set of the target genes being studied. NORMA-gene is applicable to small data sets greater than five genes of interest and is used as our primary analysis tool as it produces equal or better normalization compared to the delta-delta ct method.
Leflunomide affects gene transcription thus impacting upon metabolic and neural crest pathways. Therefore, using reference vs. target normalisation is not appropriate to measure gene expression. HiSeq2000 platform and reads were mapped to the reference X. tropicalis genome JGI7.1 using BWA allowing one mismatch.
ChIP-sequencing
Small molecule compound treatment
The small molecule compound leflunomide (Sigma) was dissolved in DMSO to make a 10 mM stock. This was then diluted directly into the embryos media 0.1xMMR. DMSO was added to the media as a control (Tomlinson et al., 2012) . 
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